VLA
Click for more information
0.00% $1.75 viralytics limited

Mercks revenue from Keytruda in the Oct 17 quarter was...

  1. 3rddoor
    74 Posts.
    lightbulb Created with Sketch. 4
    clock Created with Sketch.
    23/02/18
    13:46
    Post #: 31290901
    Mercks revenue from Keytruda in the Oct 17 quarter was US$1billion, so extrapolating the yearly revenue will be US$4billion so if Cavatak makes Keytruda 10% more sales Merck will have made their money in a year (give or take the cost of finalizing the approvals). Given that Cavatak actually showed better efficacy and safety profiles in 2015 than their product this valuation seems cheap.
    Last edited by 3rddoor: 23/02/18
    VLA Price at posting: $1.69 Sentiment: Buy Disclosure: Held
    Likes Created with Sketch. 5  Upvote
    lightbulb Created with Sketch.  Great analysis
    Stroke 3 Created with Sketch. Comments Created with Sketch. Reply

  2. Top Stories

 
watchlist Created with Sketch. Add VLA (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.